CC-99282 is a potent and orally active cereblon (CRBN) E3 ligase modulator (CELMoD). CC-99282 co-opts CRBN to induce potent and targeted degradation of Ikaros and Aiolos. CC-99282 can be used for researching non-Hodgkin lymphomas[1].
[1]. J.-M. Michot, et al. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS. Hematological Oncology. Volume 39, Issue S2, Jun. 2021.
















